Meglumine antimoniate

Generic Name: Meglumine antimoniate

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₈NO_₈Sb

CAS Number: 133-51-7

Unique Ingredient Identifier: 75G4TW236W

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous Leishmaniasis

Phase 2

Completed

Conditions: Cutaneous Leishmaniasis

Interventions: Drug: GMCSF plus Antimony reduced dose
Drug: Meglumine antimoniate

First Posted Date: 2009-09-09

Last Posted Date: 2009-09-09

Lead Sponsor: Hospital Universitário Professor Edgard Santos

Target Recruit Count: 40

Registration Number: NCT00973128

Locations: 🇧🇷
Health Post of Corte de Pedra, Valença, Bahia, Brazil

Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients

Phase 4

Completed

Conditions: Localized Cutaneous Leishmaniasis

Interventions: Drug: Meglumine antimoniate

First Posted Date: 2009-01-08

Last Posted Date: 2010-10-08

Lead Sponsor: University of Brasilia

Target Recruit Count: 13

Registration Number: NCT00818818

Locations: 🇧🇷
Health Center Unit of Corte de Pedra, Corte de Pedra, Presidente Tancredo Neves, Bahia State, Brazil

Oral Miltefosine for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia

Phase 3

Conditions: Cutaneous Leishmaniasis

Interventions: Drug: Miltefosine
Drug: Meglumine antimoniate

First Posted Date: 2007-06-18

Last Posted Date: 2010-02-17

Lead Sponsor: Centro Internacional de Entrenamiento e Investigaciones Médicas

Target Recruit Count: 150

Registration Number: NCT00487253

Treatment of Cutaneous Leishmaniasis With Meglumine Antimoniate Versus Meglumine Antimoniate and Allopurinol

Not Applicable

Completed

Conditions: Leishmaniasis, Cutaneous

Interventions: Drug: meglumine antimoniate, allopurinol
Drug: meglumine antimoniate

First Posted Date: 2007-05-31

Last Posted Date: 2010-06-02

Lead Sponsor: Combined Military Hospital, Pakistan

Target Recruit Count: 400

Registration Number: NCT00480883

Locations: 🇵🇰
Combined Military Hospital, Kharian Cantonment, Punjab, Pakistan

Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis

Phase 4

Completed

Conditions: Cutaneous Leishmaniasis

Interventions: Drug: Meglumine antimoniate

First Posted Date: 2006-04-25

Last Posted Date: 2009-01-22

Lead Sponsor: University of Brasilia

Target Recruit Count: 280

Registration Number: NCT00317980

Locations: 🇧🇷
Núcleo de Medicina Tropical, University of Brasilia, Brasilia, Distrito Federal, Brazil

Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis

Phase 3

Terminated

Conditions: Cutaneous Leishmaniasis

Interventions: Drug: meglumine antimoniate
Drug: controlled nitric oxide releasing patch

First Posted Date: 2006-04-25

Last Posted Date: 2010-11-24

Lead Sponsor: Fundación Cardiovascular de Colombia

Target Recruit Count: 178

Registration Number: NCT00317629

Locations: 🇨🇴
Fundación Cardiovascular de Colombia, Floridablanca, Santander, Colombia

Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil

Phase 2

Completed

Conditions: Leishmaniasis

First Posted Date: 2000-02-25

Last Posted Date: 2005-06-24

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 375

Registration Number: NCT00004755

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy